Oncotarget: Cancer Information Resource

Home / Oncotarget: Cancer Information Resource

Cancer has been one of the most life-threatening diseases on Earth, and even with the advancement of technology today, the condition remains incurable. Cancer has been around since prehistory, and it has already claimed millions of lives. Scientists have been cooperating and coordinating with one another to find a cure for the dreaded disease. Visit Oncotarget’s profile page at Facebook. Their efforts focus on the creation of treatment that will exterminate cancer cells entirely without any side effects or chances of it coming back. Every time there is a discovery about cancer, the scientists would publish the latest information in their scientific journals, and one of the most popular is Oncotarget. This weekly publication is made available to the public and the scientists around the world through a website, and the articles published have been reviewed carefully by a panel of dedicated oncologists. Oncotarget focuses solely on cancer-related information, including the present condition of the disease and the status of the research for a cancer cure. The first issue of Oncotarget was released in 2010, and it was published with the assistance from Impact Journals. The publication is currently being monitored and supervised by its editors in chief, Dr. Mikhail Blagosklonny, an oncologist from Roswell Park Center Institute, and Andrei V. Gudkov, his colleague. Check Oncotarget journal at scimagojr.com

Dr. Mikhail Blagosklonny and Andrei V. Gudkov became known throughout the scientific community because of their research which states that rapamycin, a substance used for cancer treatment, has anti-aging properties. They also claimed that using rapamycin can rejuvenate the cells of an individual, which is essential for extending their lives. This study was published through Oncotarget, and while the scientific community initially dismissed their research as a form of fiction, many scientists have now agreed to the study introduced by Dr. Mikhail Blagosklonny and Andrei V. Gudkov. The two editors in chief of Oncotarget has been the subject of interviews and press conferences these past few days because of the current status of their findings of rapamycin, and they claim that the supplement is going to be released soon. Oncotarget keeps on publishing new articles every week, including new methods of eliminating cancer cells from the Norris Cotton Cancer Center.

Know more: https://www.researchgate.net/journal/1949-2553_Oncotarget

Leave a Reply

Your email address will not be published. Required fields are marked *